Enzon
Executive Summary
Signs non-exclusive licensing agreement with National Institutes of Health to develop cancer detection agents based on monoclonal antibodies developed by NIH. Enzon will continue the development of single-chain antigen-binding proteins (SCA) based on these MAbs, which include CC49, which may have potential in the detection of breast, lung and colorectal cancers. Enzon plans to file an IND for SCA-CC49 "later this year," the company says.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth